Thanks to jo jo for the link to the interview.
I've transcribed some of the more interesting quotes from the interview here:
26:37 ...in a rather large number of patients, there have been some sort of reports over the years, and we've been doing this now, work on this drug since the mid-1990s, and hundreds and hundreds of patients with malignant brain tumours have taken clomipramine, albeit as anecdotal cases and indeed at different dose levels. I think it's very difficult to put your hand on your heart and say that this is something that's working across the board because we don't know the circumstances. When patients are diagnosed with malignant brain tumors increasingly they go onto the internet, and they look for things, and they start self-medicating...
29:05 We need to initiate a properly controlled clinical trial and we need to design that trial appropriately. We're going to be given a clinical trial, if indeed we're given a trial at all, if we do get permission for a clinical trial, the design of it may not give us the answers that are there to be had. In other words if we have this tagged on at the end as a sort of a "salvage therapy" for patients who've already undergone a series of other therapeutic approaches, we may end up with a patient there whose cells really are just not going to be responsive to this approach.
29:56 I think the design of the trial as well as the initiation of the trial is very important in this context. There are a number of patients, a large number of patients out there who I'm absolutely certain have done very well. You have to extrapolate to why they've done very well. Those patients happen to correlate with [those] that were taking clomipramine so you can make up your own mind on this.